Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NEK2 | P51955 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435703 | 0.86 | MAPT (0.57) | MALT1KDM4ELMNAKMT2AMEN1 | |
| SCHEMBL2425939 | 0.85 | MALT1 (0.64) | MALT1KDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14334510 | 0.84 | MALT1 (0.60) | MALT1KDM4ERECQLKMT2ANEK2 | |
| SCHEMBL4876457 | 0.84 | MALT1 (0.60) | MALT1KDM4EKCNMA1RECQLKMT2A | |
| SCHEMBL2080112 | 0.83 | KDM4E (0.67) | MALT1KDM4ERECQLLMNAKMT2A | |
| SCHEMBL4524152 | 0.83 | NEK2 (0.67) | MALT1KDM4ERECQLKMT2ANEK2 | |
| SCHEMBL14335272 | 0.83 | MALT1 (0.61) | MALT1KDM4ERECQLKMT2ANEK2 | |
| SCHEMBL4697198 | 0.82 | HRH3 (0.53) | MALT1KDM4ERECQLKMT2A | |
| SCHEMBL14334180 | 0.82 | MALT1 (0.52) | MALT1KDM4ERECQLKMT2ANEK2 | |
| SCHEMBL4103009 | 0.80 | MAPT (0.68) | MALT1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012176123-A1 | 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012176123-A1 | 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| US-7501440-B2 | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-10 | — | — | US | disclosed |
| US-20040266768-A1 | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266768-A1 | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use | SLC5A2, HPD, DPP4 | MALT1 4475/4885KDM4E 1444/4885KCNMA1 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.